Literature DB >> 25136005

EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.

Maiken Cavling Arendrup1, Susan Howard2, Cornelia Lass-Flörl3, Johan W Mouton4, Joseph Meletiadis5, Manuel Cuenca-Estrella6.   

Abstract

The EUCAST E.DEF9.1 standard recommends standardization of the inoculum concentration by conidium counting using a hemocytometer rather than a spectrophotometer. In this study, we investigated whether the choice of these methods influenced isavuconazole MICs. A blinded collection of 30 molecularly characterized azole-resistant isolates and 10 wild-type Aspergillus fumigatus isolates was shared with four different laboratories. Additionally, each laboratory selected approximately 100 A. fumigatus isolates and 50 isolates each of A. flavus, A. nidulans, A. niger, and A. terreus (1,237 isolates in total). Three laboratories (laboratories 1 to 3) used conidium counting. One laboratory standardized the inoculum using a spectrophotometer (that is, by use of the optical density [OD]) and is referred to as the OD laboratory. Correlation coefficients, intraclass correlation coefficients, and essential agreement were calculated, and 2-log-unit differences were assessed (paired t test). The MIC range for the blinded collection was 0.25 to 16 mg/liter, and a 1-dilution-step difference between the MIC50 and MIC90 across the four laboratories was detected and a 2-dilution-step difference between the modal MICs was detected. Compared to the results for laboratories 1 and 2, a significant correlation was found for the OD laboratory MIC data (correlation coefficients, 0.85 and 0.93, respectively; intraclass correlation coefficients, 0.88 and 0.96, respectively). The number of mutant isolates whose MICs overlapped those of the wild-type isolates was the lowest for the OD laboratory (14/30 [46.7%] mutant isolates), whereas the numbers were 18/30 (60%) isolates for laboratory 1, 17/30 (56.7%) isolates for laboratory 2, and 21/30 (70%) isolates for laboratory 3. For the A. flavus, A. fumigatus, A. nidulans, A. niger, and A. terreus isolates, comparative analysis again defined the MIC distributions from the OD laboratory to be in excellent agreement with those from laboratories 1 and 2 across all five Aspergillus spp. The findings suggest that EUCAST testing using OD determination is an appropriate alternative for standardization of Aspergillus inoculum concentrations.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25136005      PMCID: PMC4249446          DOI: 10.1128/AAC.03779-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans.

Authors:  E Petrikkou; J L Rodríguez-Tudela; M Cuenca-Estrella; A Gómez; A Molleja; E Mellado
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi.

Authors:  A Aberkane; M Cuenca-Estrella; A Gomez-Lopez; E Petrikkou; E Mellado; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

3.  Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi.

Authors:  J L Rodriguez-Tudela; Erja Chryssanthou; Evangelia Petrikkou; Juan Mosquera; David W Denning; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole.

Authors:  M C Arendrup; M Cuenca-Estrella; C Lass-Flörl; W W Hope
Journal:  Clin Microbiol Infect       Date:  2012-04-30       Impact factor: 8.067

5.  Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; T M Kerkering
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

6.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

7.  Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors:  M Cuenca-Estrella; M C Arendrup; E Chryssanthou; E Dannaoui; C Lass-Florl; P Sandven; A Velegraki; J L Rodriguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2007-08-13       Impact factor: 8.067

8.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William Hope
Journal:  Clin Microbiol Infect       Date:  2012-05-08       Impact factor: 8.067

9.  EUCAST technical note on voriconazole and Aspergillus spp.

Authors:  W W Hope; M Cuenca-Estrella; C Lass-Flörl; M C Arendrup
Journal:  Clin Microbiol Infect       Date:  2013-02-15       Impact factor: 8.067

10.  Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.

Authors:  Susan J Howard; Cornelia Lass-Flörl; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maiken C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

View more
  2 in total

Review 1.  Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.

Authors:  Suganthini Krishnan Natesan; Pranatharthi H Chandrasekar
Journal:  Infect Drug Resist       Date:  2016-12-07       Impact factor: 4.003

2.  Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates.

Authors:  Maiken Cavling Arendrup; Paul Verweij; Henrik Vedel Nielsen
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.